Currently, there are approx. 20+ key companies actively working in the Multiple System Atrophy therapeutics market. Emerging therapies are expected to transform the treatment scenario in the coming years immensely.
DelveInsight’s “Multiple System Atrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Multiple System Atrophy Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Multiple System Atrophy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Multiple System Atrophy: An Overview
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by symptoms that affect the autonomic nervous system (the part of the nervous system that controls involuntary action such as blood pressure or digestion) and movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord.
Currently, there are no treatments to delay the progressive neurodegeneration of MSA, and there is no cure. There are treatments to help people cope with the symptoms of MSA.
Multiple System Atrophy Market Key Facts
According to the “National Institute of Neurological Disorders and Stroke”, MSA is a rare disease, affecting potentially 15,000 to 50,000 Americans, including men and women and all racial groups. Symptoms tend to appear in a person’s 50s and advance rapidly over the course of 5 to 10 years, with progressive loss of motor function and eventual confinement to bed.
The standardized prevalence rates indicate 4–5 cases per 100,000 persons. In the age group >55 years, 17–29 cases per 100,000 persons have been observed. In Italy, 4,900 prevalent cases have been estimated based on Bower et al.’s study (Vanacore et al.).
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Multiple System Atrophy market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Multiple System Atrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Multiple System Atrophy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Multiple System Atrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple System Atrophy market or expected to get launched during the study period. The analysis covers Multiple System Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Multiple System Atrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Key Developments in the Multiple System Atrophy Therapeutics Market
On Sept. 20, 2022, Alterity Therapeutics announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to evaluate its Multiple System Atrophy (MSA) therapy, ATH434. With the approval of IND from the FDA, Alterity is all set to conduct its Phase 2 clinical trial in the U.S. Alterity’s ATH434 is designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration.
The Multiple System Atrophy Market Size is anticipated to increase in the coming years owing to the rise in the prevalent population in the 7MM. The extensive research and development activities of pharmaceutical companies for developing therapies for Multiple System Atrophy will significantly impact the market growth.
Learn How Multiple System Atrophy Market Will Evolve by 2032 @
Multiple System Atrophy Therapeutics Analysis
There are approx. 20+ key companies which are developing therapies for Multiple System Atrophy. Currently, Biohaven Pharmaceuticals has its Multiple System Atrophy drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Multiple System Atrophy (MSA) Market Include:
Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, Theravance Biopharma, and many others.
Multiple System Atrophy Emerging Drugs Covered in the report include
• DVerdiperstat (Biohaven Pharmaceuticals)
• DLu AF82422 (Lundbeck A/S)
• DATH434 (Alterity Therapeutics)
And many more
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More –
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Multiple System Atrophy Competitive Intelligence Analysis
4. Multiple System Atrophy Market Overview at a Glance
5. Multiple System Atrophy Disease Background and Overview
6. Multiple System Atrophy Patient Journey
7. Multiple System Atrophy Epidemiology and Patient Population (In US, EU5, and Japan)
8. Multiple System Atrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Multiple System Atrophy Unmet Needs
10. Key Endpoints of Multiple System Atrophy Treatment
11. Multiple System Atrophy Marketed Products
12. Multiple System Atrophy Emerging Drugs and Latest Therapeutic Advances
13. Multiple System Atrophy Seven Major Market Analysis
14. Attribute Analysis
15. Multiple System Atrophy Market Outlook (In US, EU5, and Japan)
16. Multiple System Atrophy Access and Reimbursement Overview
17. KOL Views on the Multiple System Atrophy Market
18. Multiple System Atrophy Market Drivers
19. Multiple System Atrophy Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Metastatic Triple-negative Breast Cancer (mTNBC) Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the mTNBC Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States